Recipharm acquires Flamel Technologies facility in France

27 November 2014

Swedish pharmaceutical contract development and manufacturing organization Recipharm AB and French drug delivery firm Flamel Technologies (Nasdaq: FLML) have entered into a long term collaboration and signed an agreement whereby Recipharm will purchase Flamel’s development and manufacturing facility located in Pessac, France.

Recipharm will significantly expand its pharmaceutical development capacity and technical capabilities to provide easier access for development services to its French and other customers. Recipharm will also provide development and manufacturing support to Flamel under a long term services agreement.

This new partnership allows Flamel to retain access to the development and manufacturing capabilities of Pessac and gain the possibility to use any of Recipharm’s other facilities for the development or manufacture of its proprietary pipeline. Recipharm will also assume development and manufacturing agreements with other companies and as well as an agreement providing a royalty income.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK